ISLET - A European project innovating advanced cell-therapy for Diabetes
ISLET is a 5-year 8 million Euro project bringing together 11 European partners with a shared goal: to pioneer a cell-therapy for Type 1 Diabetes. The unique multi-disciplinary team of scientific expertise has the power to translate rigorous research into a working therapy to improve the lives of people living with diabetes.
By 2025 ISLET aims to:
Manufacture clusters of beta cells for cell-therapy ready for Phase 1 clinical trials – Our first generation cell-therapy product
Create Good Manufacturing Procedure compliant clusters of beta and alpha cells (Islet – like clusters) for cell-therapy, ready for manufacturing – Our next generation cell- therapy product
Innovate and road test a cell-therapy product pipeline. We will also bring innovative solutions to a common bottleneck namely predicting the therapeutic capacity of stem cell products.
Engage, collaborate, communicate with those living with diabetes, and deliver a transparent, ambitious, enabling and exciting programme of public engagement and communication.
Discover more about ISLET’s work at:
Quotes about ISLET:
“We are extremely excited and honoured that the EU are continuing to support this vital work in driving forward a stem cell therapy for Diabetes. The immensely talented pan-European ISLET team highlights the strength in collaboration between institutions. It is only by working together transparently in this way that we can fulfill the promise that stem cell technology offers to human health globally.” - Professor Henrik Semb, scientific coordinator
“IDF Europe is hugely excited to be participating in ISLET, which we believe has the potential to pave the way for a Type 1 Diabetes cure in the future. The funding allocated to this project will have a huge effect on our ability to effectively represent the voice of, and improve the lives of people living with diabetes and connect all relevant stakeholders to ensure that knowledge is shared as broadly and rapidly as possible for maximum impact.” - Professor Dr Sehnaz Karadeniz, IDF Europe Chair